Literature DB >> 22217949

COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation.

Keith G Heinzerling, James T McCracken, Aimee-Noelle Swanson, Lara A Ray, Steven J Shoptaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22217949      PMCID： PMC3597465          DOI： 10.1097/JCP.0b013e318240a48e

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  8 in total

1.  An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response.

Authors:  Brody A Flanagin; Edwin H Cook; Harriet de Wit
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-09-05       Impact factor: 3.568

2.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

Authors:  H M Lachman; D F Papolos; T Saito; Y M Yu; C L Szumlanski; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1996-06

3.  Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine.

Authors:  Ajna Hamidovic; Andrea Dlugos; Abraham A Palmer; Harriet de Wit
Journal:  Psychiatr Genet       Date:  2010-06       Impact factor: 2.458

Review 4.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

5.  Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.

Authors:  Keith G Heinzerling; Aimee-Noelle Swanson; Soeun Kim; Lisa Cederblom; Ardis Moe; Walter Ling; Steven Shoptaw
Journal:  Drug Alcohol Depend       Date:  2010-01-25       Impact factor: 4.492

6.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

7.  Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep.

Authors:  S Bodenmann; S Xu; U F O Luhmann; M Arand; W Berger; H H Jung; H P Landolt
Journal:  Clin Pharmacol Ther       Date:  2008-11-26       Impact factor: 6.875

8.  OPRM1 gene variants modulate amphetamine-induced euphoria in humans.

Authors:  A M Dlugos; A Hamidovic; C Hodgkinson; P H Shen; D Goldman; A A Palmer; H de Wit
Journal:  Genes Brain Behav       Date:  2010-11-02       Impact factor: 3.449
  8 in total
  8 in total

1.  Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use.

Authors:  Keith G Heinzerling; Steven Shoptaw
Journal:  Gend Med       Date:  2012-03-23

2.  Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Authors:  E C Eastwood; T J Phillips
Journal:  Genes Brain Behav       Date:  2013-11-18       Impact factor: 3.449

Review 3.  The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury.

Authors:  John D Finan; Shreya V Udani; Vimal Patel; Julian E Bailes
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

5.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

6.  Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction.

Authors:  Mariana Cherner; Caitlin W-M Watson; Rowan Saloner; Laura E Halpin; Arpi Minassian; Sarah S Murray; Florin Vaida; Chad Bousman; Ian Everall
Journal:  Addict Behav       Date:  2019-06-12       Impact factor: 4.591

7.  Transcranial Direct Current Stimulation to Improve the Dysfunction of Descending Pain Modulatory System Related to Opioids in Chronic Non-cancer Pain: An Integrative Review of Neurobiology and Meta-Analysis.

Authors:  Maxciel Zortea; Leticia Ramalho; Rael Lopes Alves; Camila Fernanda da Silveira Alves; Gilberto Braulio; Iraci Lucena da Silva Torres; Felipe Fregni; Wolnei Caumo
Journal:  Front Neurosci       Date:  2019-11-18       Impact factor: 4.677

8.  Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population: a case-control study.

Authors:  Mahla Asghari; Soheila Abedini; Sohrab Saghafi Khadem; Amir Tajbakhsh; Maliheh Alimardani; Abolfazl Nesaei Bajestani; Forough Alipoor; Maryam Alidoust; Amir Savardashtaki; Peyman Hashemian; Alireza Pasdar
Journal:  BMC Med Genomics       Date:  2021-01-26       Impact factor: 3.063
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.